Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
rvasiliigion,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MCDADE MARK			2. Issuer Name and Ticker or Trading Symbol Tourmaline Bio, Inc. [TRML]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
- INICOTI		<u> </u>			3. Date of Earliest Transaction (Month/Day/Year)								_	X Dire	ctor er (give tit			Owner er (specify	
(Last)	(Fi	rst) (I	Middle))		01/29/2024								belo	w)				
C/O QIMING U.S. VENTURES MANAGEMENT, LLC				4. If	Line)									or Joint/Group Filing (Check Applicable					
11100 NE 8TH ST., SUITE 200														X Form filed by One Reporting Person Form filed by More than One Reporting					
(Street) BELLEV	Street) BELLEVUE WA 98004						Rule 10b5-1(c) Transaction Indication												
(City) (Chaty) (77a)				$ _{\Box}$	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to														
(City) (State) (Zip)					satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
1 Title of 9	Society (Inc		I - IN	2. Transaction		2A. De		ACC	Juirec 3.	וט, ג	-			5. Amo		6 04	nership	7. Nature of	
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day		Execution		tion Da	on Date,	Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			and Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock		01/29/2024					P		100,000	A	\$32.	5 448	448,431		I	By Qiming U.S. Healthcare Fund III,L.P. ⁽¹⁾			
Common	Stock													5	18		D		
Common Stock												183,177			I	By Qiming U.S. Healthcare Fund I,L.P. ⁽²⁾			
Common	Common Stock												110,083			I	By Qiming U.S. Healthcare Fund II,L.P. ⁽³⁾		
		Tal	ble II								oosed of, o				d		,		
1. Title of Derivative Security (Instr. 3)	ritle of 2. ivative Conversion Date Secution Date, and Execution Date, and Execution Date, if any		4. Trans	saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		mber ative rities ired esed	Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5) 8. Price of Derivative Security Security Genefici Owned Followin Reporter Transact (Instr. 4)		ve es lally Direct (I or Indire (I) (Instr.		Beneficial Ownership ct (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date		or Number of Shares						

Explanation of Responses:

- 1. The securities are directly held by Qiming U.S. Healthcare Fund III, L.P. ("Qiming III"). Qiming U.S. Healthcare GP III, L.L. ("Qiming GP III") is the sole general partner of Qiming III. The Reporting Person is a managing member of Qiming GP III and may be deemed to share voting and dispositive power over the securities held by Qiming III. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- 2. The securities are directly held by Qiming U.S. Healthcare Fund I, L.P. ("Qiming"). Qiming U.S. Healthcare GP I, LLC ("Qiming GP") is the sole general partner of Qiming. The Reporting Person is a managing member of Qiming GP and may be deemed to share voting and dispositive power over the securities held by Qiming. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- 3. The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming II"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP II") is the sole general partner of Qiming II. The Reporting Person is a managing member of Qiming GP II and may be deemed to share voting and dispositive power over the securities held by Qiming II. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

/s/ Mark McDade

01/31/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.